Kim Sung Jin, Park Myungchan, Choi Ahnryul, Yoo Sangjun
Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung 25440, Republic of Korea.
Department of Urology, Haeundae Paik Hospital, Inje University College of Medicine, Busan 47392, Republic of Korea.
Pharmaceuticals (Basel). 2024 Jan 13;17(1):112. doi: 10.3390/ph17010112.
This review systematically addresses the correlation between the microbiome and prostate cancer and explores its diagnostic and therapeutic implications. Recent research has indicated an association between the urinary and gut microbiome composition and prostate cancer incidence and progression. Specifically, the urinary microbiome is a potential non-invasive biomarker for early detection and risk evaluation, with altered microbial profiles in prostate cancer patients. This represents an advancement in non-invasive diagnostic approaches to prostate cancer. The role of the gut microbiome in the efficacy of various cancer therapies has recently gained attention. Gut microbiota variations can affect the metabolism and effectiveness of standard treatment modalities, including chemotherapy, immunotherapy, and hormone therapy. This review explores the potential of gut microbiome modification through dietary interventions, prebiotics, probiotics, and fecal microbiota transplantation for improving the treatment response and mitigating adverse effects. Moreover, this review discusses the potential of microbiome profiling for patient stratification and personalized treatment strategies. While the current research identifies the pivotal role of the microbiome in prostate cancer, it also highlights the necessity for further investigations to fully understand these complex interactions and their practical applications in improving patient outcomes in prostate cancer management.
本综述系统地探讨了微生物群与前列腺癌之间的相关性，并探讨了其在诊断和治疗方面的意义。最近的研究表明，尿液和肠道微生物群组成与前列腺癌的发病率和进展之间存在关联。具体而言，尿液微生物群是早期检测和风险评估的潜在非侵入性生物标志物，前列腺癌患者的微生物谱会发生改变。这代表了前列腺癌非侵入性诊断方法的一项进展。肠道微生物群在各种癌症治疗疗效中的作用最近受到了关注。肠道微生物群的变化会影响包括化疗、免疫疗法和激素疗法在内的标准治疗方式的代谢和效果。本综述探讨了通过饮食干预、益生元、益生菌和粪便微生物群移植来改变肠道微生物群，以改善治疗反应并减轻不良反应的潜力。此外，本综述还讨论了微生物群分析在患者分层和个性化治疗策略方面的潜力。虽然目前的研究确定了微生物群在前列腺癌中的关键作用，但也强调了进一步研究以充分理解这些复杂相互作用及其在改善前列腺癌管理中患者预后的实际应用的必要性。
